Stephan A Grupp

List of Publications by Year
in descending order

229	33,408	20817 60	4117 175
papers	citations	h-index	g-index

230	230	230	22566
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. New England Journal of Medicine, 2014, 371, 1507-1517.	27.0	4,444
2	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine, 2018, 378, 439-448.	27.0	3,680
3	Chimeric Antigen Receptorâ€"Modified T Cells for Acute Lymphoid Leukemia. New England Journal of Medicine, 2013, 368, 1509-1518.	27.0	3,021
4	Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 2014, 124, 188-195.	1.4	2,080
5	T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Science Translational Medicine, 2011, 3, 95ra73.	12.4	2,006
6	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation, 2019, 25, 625-638.	2.0	1,741
7	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine, 2015, 7, 303ra139.	12.4	1,402
8	Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discovery, 2015, 5, 1282-1295.	9.4	997
9	Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo. Molecular Therapy, 2009, 17, 1453-1464.	8.2	988
10	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discovery, 2016, 6, 664-679.	9.4	811
11	Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies. Cancer Journal (Sudbury, Mass), 2014, 20, 119-122.	2.0	624
12	CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood, 2015, 125, 4017-4023.	1.4	598
13	Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature Medicine, 2018, 24, 1499-1503.	30.7	459
14	Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nature Medicine, 2018, 24, 1504-1506.	30.7	393
15	Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Critical Care Medicine, 2017, 45, e124-e131.	0.9	357
16	Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARSâ€"CoV-2. Journal of Clinical Investigation, 2020, 130, 5967-5975.	8.2	319
17	Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. Cancer Discovery, 2018, 8, 944-957.	9.4	313
18	Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. Journal of Hematology and Oncology, 2018, 11, 35.	17.0	302

#	Article	IF	Citations
19	Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood, 2017, 130, 2317-2325.	1.4	273
20	Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Advances, 2020, 4, 5414-5424.	5.2	263
21	Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood, 2016, 127, 1656-1665.	1.4	255
22	Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Science Translational Medicine, 2016, 8, 320ra3.	12.4	224
23	Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma. JAMA - Journal of the American Medical Association, 2019, 322, 746.	7.4	220
24	High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model. Cancer Immunology Research, 2018, 6, 36-46.	3.4	192
25	Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood, 2015, 125, 1759-1767.	1.4	189
26	Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. Cancer Immunology Research, 2018, 6, 1100-1109.	3.4	189
27	Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction. Cancer Discovery, 2020, 10, 552-567.	9.4	184
28	Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. , 2018, 6, 137.		182
29	Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood, 2014, 124, 1372-1377.	1.4	178
30	IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood, 2015, 125, 3501-3508.	1.4	177
31	Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood, 2018, 131, 995-999.	1.4	170
32	Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2018, 24, 6175-6184.	7.0	170
33	NaÃ¯ve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers. Cancer Discovery, 2019, 9, 492-499.	9.4	167
34	Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood, 2016, 127, 17-28.	1.4	165
35	Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2020, 38, 415-422.	1.6	162
36	Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. Journal of Immunological Methods, 2016, 434, 1-8.	1.4	150

#	Article	IF	Citations
37	Chimeric Antigen Receptorâ€“ and TCR-Modified T Cells Enter Main Street and Wall Street. Journal of Immunology, 2015, 195, 755-761.	0.8	147
38	CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Advances, 2019, 3, 3539-3549.	5.2	145
39	Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood, 2017, 129, 177-187.	1.4	138
40	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
41	Monocyte lineageâ€“derived IL-6 does not affect chimeric antigen receptor T-cell function. Cytotherapy, 2017, 19, 867-880.	0.7	116
42	Eradication of B-ALL using chimeric antigen receptorâ€“expressing T cells targeting the TSLPR oncoprotein. Blood, 2015, 126, 629-639.	1.4	110
43	Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. Journal of Clinical Oncology, 2021, 39, 920-930.	1.6	110
44	Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia. Blood, 2018, 132, 556-556.	1.4	106
45	Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. , 2019, 7, 276.		101
46	Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.. Journal of Clinical Oncology, 2016, 34, 3011-3011.	1.6	98
47	Final results from a defibrotide treatmentâ€<scp>IND</scp> study for patients with hepatic venoâ€occlusive disease/sinusoidal obstruction syndrome. British Journal of Haematology, 2018, 181, 816-827.	2.5	95
48	Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2021, 39, 3044-3055.	1.6	94
49	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nature Reviews Clinical Oncology, 2018, 15, 218-218.	27.6	93
50	Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. Journal of Clinical Oncology, 2022, 40, 932-944.	1.6	93
51	Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy, 2014, 16, 619-630.	0.7	90
52	Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nature Medicine, 2021, 27, 842-850.	30.7	88
53	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)â€“an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation, 2019, 54, 1868-1880.	2.4	86
54	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e76-e85.	2.0	85

#	Article	IF	Citations
55	Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy. Cancer Discovery, 2021, 11, 2186-2199.	9.4	85
56	Tisagenlecleucel Modelâ€Based Cellular Kinetic Analysis of Chimeric Antigen Receptorâ€“T Cells. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 285-295.	2.5	83
57	Neurotoxicity after CTL019 in a pediatric and young adult cohort. Annals of Neurology, 2018, 84, 537-546.	5.3	82
58	Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response. Human Gene Therapy, 2019, 30, 168-178.	2.7	81
59	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Advances, 2019, 3, 3393-3405.	5.2	81
60	The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2017, 35, 103-103.	1.6	80
61	Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. American Journal of Hematology, 2017, 92, E11-E13.	4.1	78
62	CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. Journal of Clinical Investigation, 2019, 130, 673-685.	8.2	78
63	Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia. Blood Cancer Discovery, 2022, 3, 66-81.	5.0	70
64	Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 1710-1718.	10.7	65
65	The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Advances, 2019, 3, 4034-4042.	5.2	63
66	Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Science Advances, 2022, 8, .	10.3	63
67	Nature of Tumor Control by Permanently and Transiently Modified GD2 Chimeric Antigen Receptor T Cells in Xenograft Models of Neuroblastoma. Cancer Immunology Research, 2014, 2, 1059-1070.	3.4	62
68	TNF-Receptor Inhibitor Therapy for the Treatment of Children with Idiopathic Pneumonia Syndrome. A Joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). Biology of Blood and Marrow Transplantation, 2015, 21, 67-73.	2.0	62
69	Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia, 2020, 34, 1202-1207.	7.2	61
70	CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia. Current Treatment Options in Oncology, 2016, 17, 28.	3.0	60
71	Chimeric antigen receptor T-cell therapy for ALL. Hematology American Society of Hematology Education Program, 2014, 2014, 559-564.	2.5	58
72	Nonviral RNA chimeric antigen receptorâ€“modified T cells in patients with Hodgkin lymphoma. Blood, 2018, 132, 1022-1026.	1.4	58

#	Article	IF	Citations
73	Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis. Blood, 2016, 128, 2801-2801.	1.4	58
74	CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Lancet Haematology,the, 2021, 8, e711-e722.	4.6	57
75	Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. Biology of Blood and Marrow Transplantation, 2020, 26, 1239-1246.	2.0	56
76	CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum. Molecular and Cellular Biology, 2018, 38, .	2.3	55
77	Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood, 2011, 118, e112-e117.	1.4	49
78	Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. Biology of Blood and Marrow Transplantation, 2017, 23, 997-1004.	2.0	47
79	CAR-T cells: Early successes in blood cancer and challenges in solid tumors. Acta Pharmaceutica Sinica B, 2021, 11, 1129-1147.	12.0	47
80	Use of G-CSF in Matched Sibling Donor Pediatric Allogeneic Transplantation: A Consensus Statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatric Blood and Cancer, 2006, 46, 414-421.	1.5	46
81	Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood, 2022, 140, 619-629.	1.4	45
82	Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL. Blood, 2015, 126, 3769-3769.	1.4	40
83	Adoptive Transfer of Autologous T Cells Improves T-cell Repertoire Diversity and Long-term B-cell Function in Pediatric Patients with Neuroblastoma. Clinical Cancer Research, 2012, 18, 6732-6741.	7.0	39
84	Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CARÂT-cell therapy. Blood, 2022, 139, 2173-2185.	1.4	39
85	CD34 selection as a stem cell purging strategy for neuroblastoma: Preclinical and clinical studies. Medical and Pediatric Oncology, 2000, 35, 677-682.	1.0	38
86	Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL. Blood, 2014, 124, 1982-1982.	1.4	38
87	Rapid-sequence tandem transplant for children with high-risk neuroblastoma. Medical and Pediatric Oncology, 2000, 35, 696-700.	1.0	37
88	T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. OncoImmunology, 2016, 5, e1040216.	4.6	37
89	Beyond the storm â€" subacute toxicities and late effects in children receiving CAR T cells. Nature Reviews Clinical Oncology, 2021, 18, 363-378.	27.6	37
90	Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells. Blood, 2014, 124, 2296-2296.	1.4	37

#	Article	IF	Citations
91	Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Childrenâ€™s Oncology Group ANBL0532 Study. Journal of Clinical Oncology, 2020, 38, 2741-2752.	1.6	36
92	Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Cell Cycle, 2018, 17, 468-478.	2.6	34
93	Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent Î²-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells. Blood, 2020, 136, 3-4.	1.4	34
94	Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2016, 34, 7002-7002.	1.6	32
95	Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies. Paediatric Drugs, 2012, 14, 299-316.	3.1	31
96	Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. , 2021, 9, e002328.		31
97	A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.. Journal of Clinical Oncology, 2016, 34, LBA3-LBA3.	1.6	31
98	Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. Blood Advances, 2020, 4, 5174-5183.	5.2	30
99	Subcutaneous immunoglobulin replacement following CD19â€specific chimeric antigen receptor Tâ€cell therapy for Bâ€cell acute lymphoblastic leukemia in pediatric patients. Pediatric Blood and Cancer, 2020, 67, e28092.	1.5	29
100	Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Advances, 2021, 5, 593-601.	5.2	28
101	Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatric Blood and Cancer, 2018, 65, e27034.	1.5	26
102	Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse. Blood Advances, 2021, 5, 2128-2136.	5.2	26
103	Beginning the CAR T cell therapy revolution in the US and EU. Current Research in Translational Medicine, 2018, 66, 62-64.	1.8	24
104	CAR T cell viability release testing and clinical outcomes: is there a lower limit?. Blood, 2019, 134, 1873-1875.	1.4	24
105	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. , 2021, 9, e002287.		24
106	Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their Function. Blood, 2016, 128, 654-654.	1.4	23
107	Potential Role of IFNÎ³ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy. Blood Cancer Discovery, 2022, 3, 90-94.	5.0	23
108	Adoptive Cellular Therapy. Current Topics in Microbiology and Immunology, 2010, 344, 149-172.	1.1	22

#	Article	IF	Citations
109	Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19. Blood, 2013, 122, 163-163.	1.4	22
110	Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL. Blood, 2015, 126, 683-683.	1.4	22
111	Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL.. Journal of Clinical Oncology, 2016, 34, 3009-3009.	1.6	22
112	Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells â€˜off the shelfâ€™?. Nature Reviews Clinical Oncology, 2021, 18, 195-196.	27.6	21
113	Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. Leukemia, 2022, 36, 1508-1515.	7.2	21
114	Neuroblastoma: Issues in Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, S92-S100.	2.0	20
115	Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1^{c259}t in HLA-A2⁺ patients with synovial sarcoma (NCT01343043).. Journal of Clinical Oncology, 2017, 35, 3000-3000.	1.6	20
116	Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470. Medical and Pediatric Oncology, 2000, 35, 673-676.	1.0	19
117	Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: Saving for a rainy day. Pediatric Blood and Cancer, 2006, 46, 719-722.	1.5	19
118	Cytokine Release Syndrome after Haploidentical Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1736-1737.	2.0	19
119	Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia. Expert Review of Anticancer Therapy, 2018, 18, 959-971.	2.4	19
120	Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. Blood, 2012, 120, 739-739.	1.4	19
121	False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy. Blood, 2018, 131, 2596-2598.	1.4	18
122	Dissecting the Tumorâ€“Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach. Clinical Cancer Research, 2020, 26, 3505-3513.	7.0	18
123	Veno-occlusive disease after high-dose busulfanâ€“melphalan in neuroblastoma. Bone Marrow Transplantation, 2020, 55, 531-537.	2.4	17
124	A safety and feasibility trial of ¹³¹Iâ€MIBG in newly diagnosed highâ€risk neuroblastoma: A Children's Oncology Group study. Pediatric Blood and Cancer, 2021, 68, e29117.	1.5	17
125	T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL. Blood, 2013, 122, 67-67.	1.4	17
126	Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL.. Journal of Clinical Oncology, 2016, 34, 3007-3007.	1.6	17

#	Article	IF	Citations
127	A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.. Journal of Clinical Oncology, 2016, 34, LBA3-LBA3.	1.6	17
128	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cellâ€“Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. Clinical Cancer Research, 2022, 28, 3804-3813.	7.0	17
129	Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR. Blood, 2016, 128, 281-281.	1.4	16
130	Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2017, 35, 10507-10507.	1.6	16
131	Advances in T-cell therapy for ALL. Best Practice and Research in Clinical Haematology, 2014, 27, 222-228.	1.7	15
132	CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2020, 38, 10511-10511.	1.6	15
133	In Vivo Control of Acute Lymphoblastic Leukemia by Immunostimulatory CpG Oligonucleotides.. Blood, 2006, 108, 1868-1868.	1.4	15
134	Children's Oncology Group's 2013 blueprint for research: Stem cell transplantation. Pediatric Blood and Cancer, 2013, 60, 1044-1047.	1.5	14
135	Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL. Blood, 2013, 122, 4162-4162.	1.4	14
136	T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL. Blood, 2014, 124, 380-380.	1.4	14
137	Roadblocks to success for RNA CARs in solid tumors. OncoImmunology, 2014, 3, e962974.	4.6	13
138	IFNâ€Î³ directly inhibits murine Bâ€cell precursor leukemiaâ€initiating cell proliferation early in life. European Journal of Immunology, 2017, 47, 892-899.	2.9	13
139	Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL. Blood, 2013, 122, 873-873.	1.4	13
140	Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Blood Advances, 2021, 5, 4980-4991.	5.2	12
141	Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. Blood, 2021, 138, 474-474.	1.4	11
142	CAR-T in the clinic: drive with care. Gene Therapy, 2018, 25, 157-161.	4.5	10
143	Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease. Transplantation and Cellular Therapy, 2021, 27, 988.e1-988.e7.	1.2	10
144	Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL. Blood, 2012, 120, 717-717.	1.4	10

#	Article	IF	Citations
145	Pooled analysis of Day 100 survival for defibrotideâ€treated patients with hepatic venoâ€occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation. British Journal of Haematology, 2020, 190, 583-587.	2.5	9
146	Immune Reconstitution Following TCRÎ±Î²/CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients. Transplantation and Cellular Therapy, 2021, 27, 169.e1-169.e9.	1.2	9
147	Anti-CD123 Chimeric Antigen Receptor T Cells (CART-123) Provide A Novel Myeloablative Conditioning Regimen That Eradicates Human Acute Myeloid Leukemia In Preclinical Models. Blood, 2013, 122, 143-143.	1.4	9
148	Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Blood, 2021, 138, 428-428.	1.4	9
149	Unrelated donor Î±/Î² T cellâ€“ and B cellâ€“depleted HSCT for the treatment of pediatric acute leukemia. Blood Advances, 2022, 6, 1175-1185.	5.2	9
150	Immunotherapy for Pediatric Cancer. Biology of Blood and Marrow Transplantation, 2008, 14, 33-43.	2.0	8
151	Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?. Biology of Blood and Marrow Transplantation, 2015, 21, 402-411.	2.0	8
152	Results Of The Large Prospective Study On The Use Of Defibrotide (DF) In The Treatment Of Hepatic Veno-Occlusive Disease (VOD) In Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome - Updated Results Of a Treatment IND (T-IND) Expanded Access Protocol. Blood, 2013, 122, 700-700.	1.4	8
153	Low rate of subsequent malignant neoplasms following CAR T-cell therapy. Blood Advances, 0, , .	5.2	8
154	Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia. International Journal of Hematology, 2020, 111, 303-310.	1.6	7
155	A Phase I Trial of Sirolimus (Rapamycin) in Pediatric Patients with Relapsed/Refractory Leukemia.. Blood, 2007, 110, 2834-2834.	1.4	7
156	Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies. Blood, 2015, 126, 2523-2523.	1.4	7
157	Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors. Blood, 2021, 138, 1727-1727.	1.4	7
158	A Phase 3, Randomized, Adaptive Study of Defibrotide (DF) Vs Best Supportive Care (BSC) for the Prevention of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) in Patients (pts) Undergoing Hematopoietic Cell Transplantation (HCT): Preliminary Results. Blood, 2021, 138, 749-749.	1.4	7
159	Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL. Blood, 2014, 124, 1983-1983.	1.4	6
160	Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory/Relapsed Hodgkin Lymphoma (HL). Blood, 2017, 130, 653-653.	1.4	6
161	Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers.. Journal of Clinical Oncology, 2015, 33, TPS3102-TPS3102.	1.6	6
162	CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc).. Blood, 2012, 120, 2604-2604.	1.4	6

#	Article	IF	Citations
163	High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study from Ontario, Canada. Blood, 2018, 132, 1410-1410.	1.4	5
164	Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC).. Blood, 2010, 116, 3481-3481.	1.4	5
165	In Vivo Efficacy of PI3K Pathway Signaling Inhibition for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia. Blood, 2013, 122, 2672-2672.	1.4	5
166	Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 1334-1334.	1.4	5
167	Recent developments with defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Expert Opinion on Orphan Drugs, 2019, 7, 337-347.	0.8	4
168	Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 88.e1-88.e6.	1.2	4
169	HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia. Blood, 2020, 136, 23-24.	1.4	4
170	Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells. Blood, 2020, 136, 30-32.	1.4	4
171	The Relationship of Acute Gvhd and Pre- and Post-Transplant Flow-MRD to the Incidence and Timing of Relapse in Children Undergoing Allogeneic Transplantation for High Risk ALL: Defining a Target Population and Window for Immunological Intervention to Prevent Relapse. Blood, 2012, 120, 470-470.	1.4	4
172	Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies. Blood, 2014, 124, 966-966.	1.4	4
173	Targeting HMG-CoA Reductase in Acute Lymphoblastic Leukemia (ALL): Statins Inhibit Proliferation and Induce Apoptosis in ALL Cells. Blood, 2008, 112, 2927-2927.	1.4	4
174	Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy. Blood, 2014, 124, 1110-1110.	1.4	4
175	Ikaros Mediates Antigen Escape Following CD19 CAR T Cell Therapy in r/r B-ALL. Blood, 2021, 138, 613-613.	1.4	4
176	Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies. Clinical Cancer Research, 2022, 28, 3940-3949.	7.0	4
177	Partially CD3+-Depleted Unrelated and Haploidentical Donor Peripheral Stem Cell Transplantation Has Favorable Graft-versus-Host Disease and Survival Rates in Pediatric Hematologic Malignancy. Biology of Blood and Marrow Transplantation, 2020, 26, 493-501.	2.0	3
178	Distinct Bioenergetic Features of Human Invariant Natural Killer T Cells Enable Retained Functions in Nutrient-Deprived States. Frontiers in Immunology, 2021, 12, 700374.	4.8	3
179	Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers. Bone Marrow Transplantation, 2021, 56, 2869-2870.	2.4	3
180	Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019. Blood, 2019, 134, 61-61.	1.4	3

#	Article	IF	Citations
181	A Prospective Study of G-CSF Primed Bone Marrow from Pediatric Donors as a Stem Cell Source for Allogeneic Bone Marrow Transplant: A Pediatric Blood and Marrow Transplant Consortium (PBMTC) Study.. Blood, 2005, 106, 1964-1964.	1.4	3
182	Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol. Blood, 2010, 116, 906-906.	1.4	3
183	Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol. Blood, 2011, 118, 487-487.	1.4	3
184	Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation: Exploratory Age-Group Analysis from an Expanded Access Study. Blood, 2016, 128, 66-66.	1.4	3
185	Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Childrenâ€™s Oncology Group (COG) study.. Journal of Clinical Oncology, 2016, 34, 10528-10528.	1.6	3
186	Autologous genetically engineered NY-ESO-1^{c259}T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.. Journal of Clinical Oncology, 2016, 34, TPS3101-TPS3101.	1.6	3
187	Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.. Journal of Clinical Oncology, 2018, 36, 3044-3044.	1.6	3
188	Correlation of pre-CAR CD19 expression with responses and relapses after CAR T cell therapy.. Journal of Clinical Oncology, 2018, 36, 3051-3051.	1.6	3
189	Association of higher lung dose received during total body irradiation for allogeneic hematopoetic stem cell transplantation in children with acute lymphoblastic leukemia with inferior progression-free and overall survival: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2015, 33, 10030-10030.	1.6	3
190	Thoracic duct lymphatic fluid harbors phenotypically naive T cells for use in adoptive T-cell therapy. Cytotherapy, 2020, 22, 529-535.	0.7	2
191	Targeting mTOR Signaling Leads To Complete and Durable Responses In Children With Multi-Lineage Autoimmune Cytopenias, Including ALPS, SLE, Evans and CVID. Blood, 2013, 122, 330-330.	1.4	2
192	Cardiac effects of chimeric antigen receptor (CAR) T-cell therapy in children.. Journal of Clinical Oncology, 2017, 35, 10531-10531.	1.6	2
193	Timing of initiation of defibrotide (DF) post-diagnosis of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after hematopoietic stem cell transplantation (HSCT): Final data from an expanded-access protocol.. Journal of Clinical Oncology, 2017, 35, 7047-7047.	1.6	2
194	Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL).. Journal of Clinical Oncology, 2017, 35, 10523-10523.	1.6	2
195	Refining megatherapy, improving outcome in neuroblastoma. Lancet Oncology, The, 2017, 18, 423-424.	10.7	1
196	The role of peritoneal drainage in veno-occlusive disease in pediatric patients post hematopoietic stem cell transplant. Bone Marrow Transplantation, 2018, 53, 938-941.	2.4	1
197	Bioluminescent Tracking of Human and Mouse Acute Lymphoblastic Leukemia Reveals Potent Immunogenicity of Luciferase In Some Preclinical Models of Leukemia. Blood, 2010, 116, 2140-2140.	1.4	1
198	A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431. Blood, 2011, 118, 837-837.	1.4	1

#	Article	IF	Citations
199	Results of a Large Prospective Study On the Use of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome â€“ Updated Results of a Treatment IND (T-IND) Expanded Access Protocol. Blood, 2012, 120, 738-738.	1.4	1
200	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial. Blood, 2015, 126, 737-737.	1.4	1
201	Efficacy and safety of defibrotide (DF) to treat hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after primary chemotherapy (CT): A post hoc analysis of final data.. Journal of Clinical Oncology, 2017, 35, 10513-10513.	1.6	1
202	Effect of ONC201 and bortezomib on apoptosis in non-Hodgkin'Â™s lymphoma (NHL) xenografts.. Journal of Clinical Oncology, 2017, 35, e19016-e19016.	1.6	1
203	Gene expression signatures of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with CLL and ALL.. Journal of Clinical Oncology, 2017, 35, 137-137.	1.6	1
204	Murine Ultrasonography Confirms That Rapamycin Is Effective Against Autoimmune Lymphoproliferative Syndrome (ALPS).. Blood, 2005, 106, 2386-2386.	1.4	1
205	Targeting mTOR and JAK2 in Xenograft Models of CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL). Blood, 2011, 118, 249-249.	1.4	1
206	Sustained Functional T Cell Persistence and B Cell Aplasia Following CD19-Targeting Adoptive T Cell Immunotherapy for Relapsed, Refractory CD19+ Malignacy. Blood, 2012, 120, 756-756.	1.4	1
207	Stem cells support multiple cycles of high-dose induction therapy: Lots from tots. Pediatric Blood and Cancer, 2006, 46, 715-716.	1.5	0
208	Is G-CSF-mobilized peripheral stem cell harvest harmful?â€”Response. Pediatric Blood and Cancer, 2007, 48, 597-597.	1.5	0
209	Corrigendum to â€œAdvances in T-cell therapy for ALLâ€•[Best Pract Res Clin Haematol 27 (2014) 222â€“228]. Best Practice and Research in Clinical Haematology, 2016, 29, 133.	1.7	0
210	Improving and Maintaining Responses in Pediatric Bâ€“Cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptorâ€“T Cell Therapy. Cancer Journal (Sudbury, Mass), 2021, 27, 151-158.	2.0	0
211	Unrelated Donor (URD) or Partially Matched Related Donor (PMRD) Peripheral Stem Cell Transplant (PSCT) with CD34+ Selection and CD3+ Addback for Pediatric Patients with Leukemias.. Blood, 2004, 104, 2159-2159.	1.4	0
212	IL-7 and Thymic Stromal Lymphopoietin (TSLP) Stimulate Proliferation of All Cells and Reverse mTOR Inhibitor-Induced Growth Inhibition, Suggesting a Role for IL-7RÎ± Signaling in All.. Blood, 2004, 104, 1893-1893.	1.4	0
213	Chimeric Immunoreceptor (T-Body) Targeting of Acute B-Cell Lymphoblastic Leukemia (B-ALL) through Lentivirus Engineering of Primary Human T Cells.. Blood, 2006, 108, 3267-3267.	1.4	0
214	CpG Oligonucleotides Induce Anti-Leukemia Activity in a Syngeneic Murine Model of Acute Lymphoblastic Leukemia.. Blood, 2007, 110, 2830-2830.	1.4	0
215	Signal Transduction Inhibitors in Lymphoproliferative Diseases (LPD).. Blood, 2008, 112, sci-10-sci-10.	1.4	0
216	Targeting mTOR Signaling Is An Effective Treatment Strategy for IKAROS and JAK Kinase Mutated Acute Lymphoblastic Leukemia. Blood, 2010, 116, 3251-3251.	1.4	0

#	Article	IF	Citations
217	Allogeneic Hematopoietic Cell Transplantation (HCT) for Neuroblastoma (NB): The CIBMTR Experience. Blood, 2011, 118, 3074-3074.	1.4	0
218	In vivo monitoring of JAK/STAT and PI3K/mTOR signal transduction inhibition in pediatric CRLF2-rearranged acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2012, 30, 9506-9506.	1.6	0
219	Evaluation of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Non-Stem Cell Transplant (non-SCT) Chemotherapy Patients (pts): Results From the Treatment IND (T-IND) Expanded Access Protocol and the Compassionate Use Program (CUP).. Blood, 2012, 120, 3041-3041.	1.4	0
220	Immune Profiling Suggests an IGH Signaling-Dependent Subtype of Aggressive B-ALL. Blood, 2012, 120, 1428-1428.	1.4	0
221	A Novel Model of Immune-Mediated Disease Equilibrium in Acute Lymphoblastic Leukemia. Blood, 2012, 120, 3540-3540.	1.4	0
222	Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival. Blood, 2014, 124, 2469-2469.	1.4	0
223	Updated Results from a Large, Ongoing, Treatment IND Study Using Defibrotide for Patients with Hepatic Veno-Occlusive Disease. Blood, 2014, 124, 2470-2470.	1.4	0
224	Resource utilization (RU) and toxicities after carboplatin/etoposide/melphalan (CEM) and busulfan/melphalan (BuMel) for autologous stem cell rescue (ASCR) in high-risk neuroblastoma (HRNB).. Journal of Clinical Oncology, 2015, 33, e21009-e21009.	1.6	0
225	Defibrotide for the Treatment of Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with/without Multi-Organ Dysfunction Following Chemotherapy: Results from an Ongoing Expanded Access Program. Blood, 2015, 126, 3121-3121.	1.4	0
226	Ex Vivo T-Cell Receptor Î±Î² +/CD19 +depletion of Peripheral Stem Cell Grafts for Pediatric Patients with Bone Marrow Failure (BMF) Undergoing Unrelated Donor Transplantation. Blood, 2021, 138, 171-171.	1.4	0
227	Prognostic Value of Elafin in Acute Graft-Versus-Host Disease. Blood, 2021, 138, 3900-3900.	1.4	0
228	Impact of diagnostic and end-of-induction Curie scores in tandem autologous hematopoietic cell transplant for patients with high-risk neuroblastoma: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2022, 40, 10027-10027.	1.6	0
229	Impact of socioeconomic status on survival after CD19 CART therapy.. Journal of Clinical Oncology, 2022, 40, 7013-7013.	1.6	0